Cagrilintide
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Adds a long-acting amylin satiety lane: less between-meal hunger, slower gastric emptying, and weight loss.
Cagrilintide is not FDA-approved and carries meaningful GI and fatigue side effects; use only after establishing baseline cardiometabolic labs and with awareness of the long half-life preventing rapid dose adjustment.
Adds a long-acting amylin satiety lane: less between-meal hunger, slower gastric emptying, and weight loss. Best understood as a GLP-1 plateau-breaker or stack component, not the usual first injectable obesity drug.
Fatigue/tiredness distinct from GLP-1 nausea; nausea, vomiting, diarrhea, or constipation that often peak 24-48 hours after injection; slow onset and slow washout because steady state takes weeks; variable response, especially at 0.3-0.6 mg.
A once-weekly amylin analogue with a different satiety signal than GLP-1 drugs. Standalone Phase 2 data sits around 8-11% weight loss at higher weekly doses, while CagriSema-style cagrilintide + semaglutide data reaches roughly 15-20% in trial settings.
Moderate standalone; high in combination with semaglutide or retatrutide; widely considered the most mechanistically sound add-on to GLP-1 therapy for those seeking maximum fat loss
Do not combine with other amylin-class compounds; avoid stacking with multiple GLP-1 agonists simultaneously without medical supervision given additive GI burden.
Intro
Cagrilintide (AM833) is a long-acting synthetic analogue of the pancreatic hormone amylin, developed by Novo Nordisk as an investigational obesity treatment.
Native amylin is co-secreted with insulin from pancreatic beta cells and acts on central amylin receptors (AMY1 and AMY3, formed by calcitonin receptor plus RAMP1 or RAMP3 accessory proteins) in the brain — primarily the area postrema, nucleus tractus solitarius, and hypothalamus — to suppress appetite, slow gastric emptying, and reduce food intake. Cagrilintide was engineered from the native amylin sequence via strategic amino acid substitutions (including Asn14→Ala at positions 28 and 29 to prevent aggregation) plus a C18 fatty diacid tether at Lys-25. This acylation enables slow dissociation from plasma albumin, extending the half-life from the native peptide's minutes to approximately 159–195 hours (~7–8 days), making once-weekly subcutaneous administration pharmacologically viable.
Cagrilintide's mechanism is distinct from GLP-1 receptor agonists: GLP-1 agonists (semaglutide, tirzepatide, retatrutide) act primarily via vagal afferents and peri-meal appetite suppression, while amylin acts via area postrema circuits producing inter-meal satiety and background hunger reduction. This mechanistic non-overlap is the scientific rationale for the CagriSema combination (cagrilintide + semaglutide), which in Phase 2 clinical trials achieved ~15.6% mean body weight reduction over 32 weeks in type 2 diabetes — substantially exceeding semaglutide monotherapy's ~9.4% in the same trial. As a standalone, cagrilintide produces ~8–11% body weight reduction at doses of 2.4–4.5 mg weekly over 26 weeks in Phase 2 data.
In the research peptide community, cagrilintide has rapidly gained traction since 2023–2024, primarily as a GLP-1 stack component rather than a standalone. Community use focuses on plateau-breaking (adding cagrilintide to an established GLP-1 protocol) and maximum fat-loss stacks (CagriSema or the more aggressive retatrutide + cagrilintide combination). The compound is in Phase 3 clinical development (REDEFINE-1 through REDEFINE-6 trials) as of 2025–2026.
Observed Effects
Clinical trial data (Phase 2 dose-finding, Lancet 2021): cagrilintide at 4.5 mg weekly produced mean body weight reduction of ~10.8% over 26 weeks in people with overweight or obesity, versus ~3.0% for placebo and ~9.0% for liraglutide 3.0 mg comparator. Dose-response was confirmed: 0.3 mg weekly produced no significant weight loss versus placebo; 0.6 mg onward showed progressive efficacy. In the REDEFINE Phase 2 type 2 diabetes trial (Lancet 2023), CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) produced 15.6% body weight reduction and 2.2 percentage point HbA1c reduction versus semaglutide alone's 9.4% weight reduction. A 2025 systematic review and meta-analysis (PubMed 41834765) confirmed CagriSema's superiority to semaglutide monotherapy across pooled Phase 2 data. Secondary cardiometabolic effects include modest systolic blood pressure reduction (~1-3 mmHg), fasting glucose improvement consistent with weight loss, and no adverse lipid effects. No direct beta-cell toxicity or significant cardiovascular safety signals identified in Phase 2 data.
Community-reported outcomes generally align with trial data: experienced users combining cagrilintide with semaglutide report 8-15% body weight reduction over 16-24 weeks; standalone use is more variable (2-10% over 16 weeks at 0.6-2.4 mg). The plateau-breaking effect is a consistent community signal: users who have stalled on GLP-1 monotherapy frequently report resumption of weight loss within 2-6 weeks of adding cagrilintide. One community report noted unexpected anti-inflammatory effects (subjective joint pain reduction, possibly reflecting weight loss and potential direct amylin anti-inflammatory signaling). Community-described 'background satiety' — a reduction in inter-meal hunger distinct from GLP-1's peri-meal appetite suppression — is the characteristic reported experience.
Field Reports
First-person accounts cluster around two experience patterns. The positive pattern is plateau-breaking: users on semaglutide or tirzepatide who had stalled for weeks to months often report renewed weight loss within 2–6 weeks of adding cagrilintide at steady state. The described effect is qualitatively different from GLP-1 meal-size suppression: less background hunger between meals, not simply getting full faster.
The negative pattern is low-dose nothingness: after 4–6 weeks at 0.3–0.6 mg, some users feel no appetite change. That may reflect underdosing relative to therapeutic range, slow steady-state accumulation being judged too early, or genuine individual variation in amylin sensitivity. The more coherent community advice is to hold each dose long enough, then assess 1.2–2.4 mg before declaring non-response if tolerability allows.
Fatigue is the side-effect texture that gives cagrilintide its own identity. It is not the same as GLP-1 nausea, and injecting at night may blunt nausea without preventing next-day tiredness. Users who tolerate the first 4–6 weeks often report that fatigue improves, making titration patience central to the experience.
Community Consensus
Cagrilintide's community narrative is unusual for a research peptide: it entered through obesity-drug trial literature more than practitioner folklore. The dominant framing is an amylin supercharger: a layer added to an existing GLP-1 protocol rather than a starting point.
The compound is discussed with unusual sophistication because the mechanism is clear. Users distinguish background satiety from peri-meal satiety, understand the CALCR + RAMP1/RAMP3 receptor logic, and repeatedly stress slow titration because of the 7-day half-life.
Key community tensions: (1) standalone vs combination use, because many users see standalone cagrilintide as too modest; (2) fatigue, which surprises users expecting nausea to be the main side effect; (3) low-dose non-response, especially when users judge 0.3-0.6 mg before steady state; (4) product-quality and handling trust, because purity, sterility, and cold storage can decide whether a protocol is useful or risky.
Risks & Monitoring
The dominant side effect profile of cagrilintide centers on two mechanisms. First, GI effects (nausea, vomiting, diarrhea, constipation) overlap with the GLP-1 class, though community comparisons often describe them as milder than semaglutide at equivalent weight-loss pressure. These commonly peak 24–48 hours post-injection and usually improve over the first 4–8 weeks of a dose level. Second, fatigue and tiredness appear to be an amylin-specific burden: users describe reduced energy rather than stimulation, and it may not respond to the same timing tricks used for nausea.
Additional reported side effects include mild headache during early titration, injection-site redness or swelling, and anecdotal mild bradycardia-adjacent effects at higher doses. The long half-life (~7–8 days) is the practical safety problem: once side effects are established, they can persist for roughly 4–5 weeks after stopping. In clinical trials, GI adverse events led to discontinuation in ~5–8% of participants. Low-dose non-response is also common enough to matter: no appetite change after 4–6 weeks at 0.3–0.6 mg may reflect underdosing, impatience before steady state, or genuine individual variation. Combining cagrilintide with GLP-1 agonists adds GI burden rather than replacing it.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Cagrilintide is an amylin analogue; native amylin is co-secreted with insulin. Establishing baseline glycemic status is essential before adding an amylin-pathway agent. Monitor for glucose improvement (expected secondary effect) and to exclude undiagnosed T2D.
Cagrilintide activates the calcitonin receptor (CALCR) in addition to AMY1/AMY3. Baseline calcitonin is standard monitoring for calcitonin receptor-activating compounds. Elevated baseline calcitonin warrants medical evaluation before initiating.
Establishes kidney function, liver enzymes, and electrolytes. Important for assessing whether GI side effects (vomiting, diarrhea) are causing dehydration or electrolyte disturbances, and for monitoring hepatic parameters.
Phase 2 data showed no adverse lipid effects; monitor to confirm and track metabolic improvement with weight loss over time.
Standard safety monitoring for long-term peptide protocols; baseline hematological status.
At 12–16 weeks, assess glycemic improvement as a marker of metabolic response to weight loss. HbA1c improvement is a secondary efficacy marker.
Every 6 months on-protocol: confirm calcitonin remains normal (ongoing CALCR activation monitoring) and renal/hepatic function is stable.
Avoid With
Do not combine Cagrilintide with the following. Sorted highest-severity first.
Why:Additive GI burden — nausea, vomiting, and diarrhea compound across multiple satiety-pathway drugs; caloric restriction also compounds
What to do:Stacking three or more satiety-pathway compounds simultaneously risks severe GI adverse events and muscle loss from excessive caloric restriction. If combining cagrilintide with a GLP-1 agonist, choose one primary GLP-1 agent, not two.
Why:Receptor saturation — no additive benefit expected from stacking two amylin receptor agonists; only increased side effect burden
What to do:Cagrilintide occupies AMY1/AMY3 and CALCR. Adding another amylin analogue adds nothing mechanistically while potentially adding GI and fatigue burden.
Why:CALCR competition — both cagrilintide and therapeutic calcitonin activate the calcitonin receptor; pharmacological interaction possible
What to do:Theoretical interaction; no clinical data. Calcitonin therapy is rare, but if concurrent use is considered, medical oversight is essential.
Protocols By Goal
Plateau-breaking add-on to existing GLP-1 therapy: Reported community practice often adds cagrilintide at 0.3 mg weekly while holding the existing semaglutide or tirzepatide dose stable, then titrates cagrilintide over 8-12 weeks toward 1.2-2.4 mg. Simultaneous GLP-1 escalation is usually avoided because GI and fatigue burden can stack.
CagriSema-style use: Semaglutide and cagrilintide are titrated toward the 2.4 mg + 2.4 mg combination used in Phase 2 REDEFINE-style trial material, usually over 16-24 weeks. Trial outcomes are not the same as unsupervised research-peptide use.
Aggressive fat loss (Reta + Cagri): Retatrutide plus cagrilintide appears as a four-mechanism community stack (GLP-1 + GIP + glucagon + amylin). It has no direct clinical trial data for the specific combination and carries substantial additive GI and fatigue burden; reported use is best understood as advanced experimentation, not a general protocol.
Dosing Details
Community titration patterns mirror Phase 2 trial design: 0.3 mg weekly for weeks 1-4, 0.6 mg for weeks 5-8, 1.2 mg for weeks 9-12, and 2.4 mg from weeks 13-16 onward if tolerated.
The highest Phase 2 dose arm was 4.5 mg weekly. Due to the ~7-8 day half-life, full steady-state response takes weeks; side effects and efficacy both evolve over that window.
Research-peptide versions add handling risk that trial drugs do not: sterility, dilution accuracy, cold storage, and disposal of questionable solution. Those mechanics are operational safety issues rather than reader-specific instructions.
Subcutaneous weekly use is the discussed route. Some community users prefer evening administration to sleep through the peak nausea/fatigue window in the first 12-24 hours, though fatigue can persist into the next day.
Stacks & Alternatives
The evidence-backed standard stack derived directly from Phase 2 REDEFINE trial data. Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide) for mechanistically additive satiety via non-overlapping brain circuits. CagriSema produces ~15.6% weight reduction vs ~9.4% for semaglutide alone in Phase 2. Standard dosing: semaglutide 2.4 mg + cagrilintide 2.4 mg weekly SC.
Community-popular intensive four-mechanism fat-loss stack. Retatrutide covers GLP-1, GIP, and glucagon receptors; cagrilintide adds amylin receptors (AMY1/AMY3). No clinical trial data for this specific combination. Rationale is mechanistic non-overlap across all major satiety pathways. Additive GI and fatigue burden is a practical concern; only for experienced users who have tolerated each compound separately.
Dual GLP-1/GIP agonist providing broader receptor coverage than semaglutide. Combining with cagrilintide adds the amylin pathway. Less community data than the Reta+Cagri combination. One GLP-1 Forum thread documents active use for plateau-breaking on tirzepatide. No clinical trial data.
Alternatives
Stack Cost
High stack tax: cagrilintide is once-weekly and non-hormonal, but it sits on top of the GLP-1/amylin satiety lane, adds durable GI and fatigue burden, requires slow titration because of the 7-8 day half-life, and is mainly useful after a user has already proven GLP-1 tolerance.
The article frames cagrilintide primarily as an add-on to semaglutide, tirzepatide, or retatrutide rather than a first-line standalone. Its stackingConflicts section warns against stacking multiple GLP-1 agonists simultaneously and against combining redundant amylin/CALCR compounds because the satiety-pathway and GI burdens compound.
The adverseEffects section separates cagrilintide fatigue from GLP-1 nausea and describes it as an amylin-specific tiredness or reduced-energy effect. That creates a practical energy and adherence tax even when nausea is manageable.
The article's recommendedPanels require baseline fasting glucose and HbA1c, CMP, and baseline calcitonin, with repeat glycemic and calcitonin/CMP monitoring for longer protocols. Monitoring is not as broad as hormonal or hepatic compounds, but it is more than a casual appetite-suppression add-on.
The dosingProtocols and practicalConsiderations sections emphasize weekly subcutaneous use, sterile handling, cold storage, and a 7-8 day half-life. Dose changes take weeks to fully express, so tolerability mistakes cannot be quickly reversed.
The practicalitiesSummary and practicalConsiderations sections identify cagrilintide as an investigational, not-yet-FDA-approved research peptide with variable gray-market purity. At 2.4 mg weekly it also consumes a 10 mg vial about every four weeks, and full CagriSema-style protocols add semaglutide cost on top.
- ·Treat cagrilintide as occupying the amylin/CALCR satiety lane; do not add another amylin analogue or CALCR-activating compound expecting additive benefit.
- ·If stacking with obesity drugs, pick one primary GLP-1-pathway agent and add cagrilintide slowly; the article explicitly warns against semaglutide plus tirzepatide plus cagrilintide-style multi-GLP-1 stacking.
- ·Do not escalate cagrilintide and the GLP-1 agent at the same time; the protocolsByGoal section says to hold the existing GLP-1 dose stable while cagrilintide is introduced.
- ·Budget 5-6 weeks per dose level before judging response or tolerability because the article states steady state and side-effect expression lag behind weekly dosing.
- ·Count fatigue, nausea, vomiting, constipation, and inadequate calorie or protein intake as capacity-limiting signals, especially in aggressive retatrutide plus cagrilintide protocols.
- ·Baseline metabolic monitoring with fasting glucose, HbA1c, CMP, lipid panel, CBC, and calcitonin before long protocols.
- ·Midcycle or 12-16 week glycemic reassessment to confirm expected metabolic response and detect excessive restriction risk.
- ·Ongoing calcitonin and CMP follow-up for extended use because the article treats CALCR activation and dehydration/electrolyte risk as monitoring concerns.
- ·A slow titration calendar with at least 5 weeks at each dose level before escalation or non-response judgment.
- ·GI and fatigue mitigation planning, including injection timing, hydration, electrolyte support, and readiness to pause rather than rapidly dose down.
The article's quickSummary says cagrilintide is intermediate to advanced and not recommended as a first GLP-1-class compound. Its best fit is a user already established on a GLP-1 agonist who has plateaued or wants maximum outcome.
- ·The user has never used a GLP-1 or injectable satiety agent before.
- ·The user wants a fast on/off appetite suppressant that can be adjusted within days.
- ·The user is already stacking more than one GLP-1-pathway compound.
- ·The user has active severe GI symptoms, dehydration risk, or cannot tolerate weeks of lingering side effects.
The article repeatedly emphasizes the 7-8 day half-life and states that side effects may persist for 4-5 weeks after stopping. Discontinuation is pharmacologically simple, but symptom resolution is slow.
- ·Nausea, constipation, or diarrhea can persist after the last injection.
- ·Fatigue may linger through washout because dose reduction cannot rapidly clear the compound.
- ·Appetite and plateau pressure may return as amylin-pathway exposure declines.
- ·Users who stacked with a GLP-1 may have trouble identifying which compound caused the adverse effect unless only one dose was changed at a time.
Introduce cagrilintide at 0.3 mg weekly while holding the existing GLP-1 dose stable, avoid simultaneous dose escalations, and pause escalation if GI symptoms increase.
Treat fatigue as a dose-limiting cagrilintide signal, not just a nausea-timing issue; hold the dose longer or step back rather than adding more satiety drugs.
Use the article's steady-state framing: hold each dose level long enough to judge it, and do not declare failure until 1.2-2.4 mg has been assessed with adequate time and tolerability.
Use only identity-documented material, sterile handling, and cold storage; replace questionable vials rather than escalating blindly.
The article identifies GI effects as the dominant shared satiety-pathway adverse event, and the long half-life means severe symptoms cannot be quickly reversed by a small dose adjustment.
The article's stackingRedline and stackingConflicts warn against combining multiple GLP-1 agonists simultaneously with cagrilintide because GI burden and excessive caloric restriction compound.
womenConsiderations marks pregnancy contraindicated and recommends discontinuation before conception because human fertility and pregnancy outcome data are not established.
The article's recommendedPanels make baseline glycemic status, CMP, and calcitonin part of prudent use for an amylin/CALCR compound.
Practical Setup
The 7-8 day half-life has three practical consequences: dose changes take 5-6 weeks to reach new steady state; side effects at a given dose can persist for roughly 4-5 weeks after stopping; and a missed weekly injection is less abrupt than missing a short-acting drug, but consistent weekly timing still matters.
Research-peptide cagrilintide creates operational risk around identity, sterility, dilution, cold storage, and questionable or cloudy solution. These risks are separate from the pharmacology and are a major reason the gray-market version is not interchangeable with future regulated products.
Cagrilintide is currently in Phase 3 clinical development and may eventually be displaced by regulated pharmaceutical CagriSema or standalone products. Until then, the research-peptide version carries the usual identity, purity, sterility, and cold-chain uncertainty.
Cost pressure is real: community CagriSema-style protocols often combine the cost of cagrilintide with semaglutide, making sustained use materially more expensive than a single-agent GLP-1 pathway.
Mechanism Deep Dive
Cagrilintide activates three receptor complexes: amylin receptor 1 (AMY1 = CALCR + RAMP1), amylin receptor 3 (AMY3 = CALCR + RAMP3), and the calcitonin receptor (CALCR) directly.
AMY1 and AMY3 are the primary targets mediating weight loss. These receptors are expressed in the area postrema (a circumventricular organ with a compromised blood-brain barrier permitting peripheral peptide access), the nucleus tractus solitarius, and hypothalamic nuclei including the arcuate nucleus. Activation of these circuits reduces appetite primarily by signaling inter-meal satiety — reducing the drive to eat between meals rather than reducing meal size per se. This is distinct from GLP-1 receptor agonism, which acts via vagal afferents and primarily suppresses peri-meal appetite and gastric emptying.
Pharmacological engineering: native amylin is a 37-amino acid peptide with an amidated C-terminus and intramolecular disulfide bond. It self-aggregates in solution and has a plasma half-life of minutes. Cagrilintide addresses both limitations: (1) amino acid substitutions at positions 14, 28, and 29 reduce aggregation propensity; (2) acylation with a C18 fatty diacid tether at Lys-25 enables reversible albumin binding, creating a depot effect that extends half-life to 159–195 hours. The acyl chain does not occupy the receptor binding groove — it remains exposed and mediates albumin association while the peptide backbone engages the receptor. Structural studies (Nature Communications 2025, Cao et al.) document the alpha-helical binding conformation at the receptor and confirm that the RAMP1/RAMP3 accessory proteins modulate receptor pharmacology, explaining why AMY1 and AMY3 are preferentially activated over isolated CALCR.
The amylin pathway's complementarity to GLP-1: GLP-1 receptors are expressed in gut enteroendocrine cells and vagal neurons (peripheral) and in specific hypothalamic and brainstem circuits (central). Amylin receptors are expressed primarily in circumventricular organs (area postrema) and hypothalamic circuits with some overlap but distinct receptor populations. The mechanistic non-overlap was confirmed in the Phase 1b co-administration study (PubMed 33894838), which showed no PK interaction between cagrilintide and semaglutide and additive weight loss — the two compounds do not simply compete for the same molecular targets.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Cagrilintide 4.5 mg weekly produced ~10.8% mean body weight reduction over 26 weeks vs ~3.0% placebo
Phase 2 dose-finding RCT, multicentre, randomised, double-blind, placebo- and active-controlled (Lancet 2021)
CagriSema produced 15.6% weight reduction and 2.2pp HbA1c reduction vs semaglutide alone 9.4% weight reduction
REDEFINE Phase 2 randomised, double-blind, active-controlled trial, T2D population (Lancet 2023)
CagriSema superior to semaglutide monotherapy for weight loss and HbA1c reduction across pooled Phase 2 data
Systematic review and meta-analysis (PubMed 41834765, 2025). Population: combined Phase 2 trial participants.
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 (AMY1 and AMY3)
PMC eBioMedicine 2025: mechanistic study demonstrating CALCR+RAMP1 and CALCR+RAMP3 as the primary weight-reducing receptor targets
Phase 1b PK/PD study confirmed no clinically significant interaction between cagrilintide and semaglutide 2.4 mg
Phase 1b safety/tolerability/PK/PD randomised controlled trial (PubMed 33894838)
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.